An Exploratory, Randomized, Double-blind, Placebo-controlled, Parallel Arm Trial of the Safety and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients Hospitalized With Worsening Heart Failure
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Heart failure
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi
- 27 Mar 2019 Planned End Date changed from 22 Nov 2019 to 1 Nov 2020.
- 27 Mar 2019 Planned primary completion date changed from 22 Nov 2019 to 1 Nov 2020.
- 31 Aug 2018 Biomarkers information updated